Only 27 percent of youths treated for opioid addiction receive buprenorphine or naltrexone, known as medication-assisted treatment, a new study finds.
“These medications are considered the evidence-based standard of care for opioid addiction by the American Academy of Pediatrics,” said lead researcher Dr. Scott Hadland of Boston University School of Medicine.
Buprenorphine (sold as Suboxone) has been shown to reduce cravings, while naltrexone (sold as Revia and Vivitrol) blocks the high from opioids, HealthDay reports.
The rate of opioid addiction among teens and young adults shot up almost sixfold between 2001 and 2014, the researchers note in JAMA Pediatrics.
Hadland said one reason so few young people receive medication-assisted treatment is that too few pediatricians and family doctors are trained in how to treat opioid addiction. “In light of the national opioid crisis, it’s really now more important than ever to ensure that providers are receiving the training,” he said.